Fujitsu Japan, the National Cancer Center Hospital East and US-based Paradigm Health have tested an AI-assisted system for identifying potential participants in clinical trials in Japan.

The partners used a large language model to structure patient information from electronic medical records and linked the resulting data to Paradigm’s clinical trial matching platform, according to a Fujitsu Japan statement on Thursday.

The retrospective verification study covered records from 22,334 patients in the hospital’s respiratory medicine department between June and the end of October. For a simulated trial involving EGFR gene mutations, Fujitsu processed data from 3,027 lung-cancer patients and identified 540 records with the mutation for evaluation against five eligibility criteria.

Paradigm’s platform selected 57 priority candidates and presented clinical evidence supporting those selections. Physicians subsequently reviewed the records and determined that 51 were promising candidates, Fujitsu said.

The study also found that automated overnight processing reduced the number of records requiring manual review by approximately 89 percent. The partners said the approach could help medical staff apply standardized criteria without manually searching dispersed treatment histories, test results and genomic information.

Fujitsu stressed that the output did not determine whether patients were eligible for a real trial. Final eligibility would remain subject to trial requirements, physician review and patient consent.

The work addresses a recruitment challenge in Japan, where increasingly specific genetic and biomarker criteria can make it difficult for clinical staff to identify eligible patients. Fujitsu has also framed the project as part of efforts to reduce “drug loss,” a term used for treatments available overseas that are not developed or approved in Japan.

The company plans to commercialize a service supporting the process from candidate screening through clinical trial enrollment by the end of fiscal 2027. It said the partners intend to promote adoption by medical institutions across Japan.

Paradigm separately reported preliminary findings from the research at the European Society for Medical Oncology Congress in October. The November announcement adds Fujitsu’s detailed workflow, physician-review results and commercialization target.

Fujitsu tackles ‘drug loss’ in Japan through ecosystem to accelerate digitalization of clinical trials